A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Latest Information Update: 24 Nov 2024
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IZALCO
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
Most Recent Events
- 23 May 2024 Planned number of patients changed from 68 to 71.
- 23 May 2024 Planned End Date changed from 17 Feb 2027 to 1 Mar 2027.
- 23 May 2024 Planned primary completion date changed from 14 Oct 2024 to 24 Oct 2024.